| SEQ_NO | 1 | Date of announcement | 2026/11/04 | Time of announcement | 16:12:45 |
| Subject | Urocross Expander System Officially Obtained the Market Approval from TFDA | ||||
| Date of events | 2026/11/04 | To which item it meets | paragraph 10 | ||
| Statement | 1.Date of occurrence of the event:2026/11/04 2.New drug name or code:Urocross Expander System 3.Indication: The Urocross Expander System is a retrievable, non-permanent implant system developed to improve lower urinary tract symptoms (LUTS) associated with Benign Prostatic Hyperplasia (BPH). The system gently expands the prostatic urethral tissue through a minimally invasive procedure performed under mild anesthesia, thereby relieving obstruction and improving urinary flow. 4.Planned development stages: The Urocross Expander System has officially obtained the market approval from TFDA on 2026/11/4 (Taipei Time). 5.Current development stage: (1) Submission of application / approval granted / approval not granted / results of each phase of clinical trials (including interim analysis) / occurrence of other material events affecting new drug development: The Urocross Expander System has officially obtained the market approval from TFDA (2) In the event that approval is not granted by the competent authority for the intended use, or the results of any phase of clinical trials (including interim analysis) fail to reach statistical significance, or other material events occur that may affect new drug development, the risks faced by the Company and corresponding countermeasures: Not Applicable (3) In the event that approval has been granted by the competent authority for the intended use, or the results of any phase of clinical trials (including interim analysis) reach statistical significance, or other material events occur that may affect new drug development, the Company’s future business plans and directions: Not Applicable (4) Cumulative research and development expenses incurred?G Due to the involvement of information pertaining to future global business development discussions, and to avoid impacting the deal amount while safeguarding the rights and interests of investors, the details will not be disclosed at this time. 6.Upcoming development plan: Subsequent efforts will continue to advance preparations for product launch while simultaneously conducting international strategic collaboration discussions. 7.Market situation: The probability of men suffering from BPH increases with age; approximately half of men aged 60 have histologically confirmed prostate hyperplasia, and this figure rises to 70% to 80% among men aged 70 and older. The estimated population in the United States alone with BPH is reaching 40 million. As the population continues to age, the number of BPH patients is expected to grow accordingly. According to statistics from the National Health Insurance under Taiwan Ministry of Health and Welfare, the number of people seeking medical treatment for benign prostatic hyperplasia in Taiwan exceeded 800 thousand in 2025, indicating a significant level of medical demand for this condition. According to a market research report by Grand View Research, the global market for medical devices treating BPH reached USD 1.67 billion in 2024. It is projected that from 2025 to 2033, the BPH-related market will grow at a compound annual growth rate (CAGR) of 9.4%, reaching USD 3.71 billion in 2033. 8.Any other matters that need to be specified(the information disclosure also meets the requirements of Article 7, subparagraph 8 of the Securities and Exchange Act Enforcement Rules, which brings forth a significant impact on shareholders rights or the price of the securities on public companies.): The Company has successfully obtained the market approval from TFDA, enabling it to legally commence sales activities in the Taiwan market. The team will continue to advance preparations for introducing Urocross into Taiwan’s healthcare system, while progressing key initiatives related to product supply, distribution channels, and professional education and training. Through comprehensive market readiness efforts, the team aims to enhance healthcare professionals’ understanding of the product’s characteristics and supporting clinical evidence, while taking a measured, step-by-step approach to establishing a solid foundation for its adoption in Taiwan’s healthcare enviroment. 9.New drug development requires long process, vast investments and with no guarantee in success which may pose investment risks.The investors are advised to exercise caution and conduct thorough evaluation.: |
||||